Business Standard

Wednesday, January 01, 2025 | 09:57 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Plan to use HCQ for Covid-19 treatment receives setback after death reports

Trump administration has stockpiled more than 30 million doses of hydroxychloroquine, a large chunk of which has been imported from India

HCQS consignment from India to the US | Image: Twitter/ SandhuTaranjitS
Premium

HCQS consignment from India to the US | Image: Twitter/ SandhuTaranjitS

Press Trust of India
The plan to use much touted anti-malarial drug hydroxychloroquine for treating Covid-19 patients has received a setback with more deaths being reported among those who were given the drug, according to a report.

While another report suggested that there was insufficient clinical data to either recommend or oppose the use of hydroxychloroquine for treating those infected with the deadly virus.

President Donald Trump, who has been aggressively promoting the use of hydroxychloroquine in the treatment of Covid-19 patients, said that he would look into the reports. His administration has stockpiled more than 30 million doses of hydroxychloroquine, a large chunk

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in